Highlights
– Olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III (apoC-III) mRNA, produced large, clinically meaningful reductions in triglyceride levels at 6 months versus placebo in two randomized, double-blind trials (CORE-TIMI 72a and CORE2-TIMI 72b).
– The therapy was associated with a significantly lower incidence of acute pancreatitis (mean rate ratio 0.15; 95% CI, 0.05–0.40; P<0.001).
